Engineered endolysin of Klebsiella pneumoniae phage is a potent and broad-spectrum bactericidal agent against “ESKAPEE” pathogens
Frontiers in Microbiology · 09.05.2024 · 15
DOI: 10.3389/fmicb.2024.1397830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 09.05.2024. Verfasst von Wei Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tuberculosis, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The rise of antimicrobial resistance in ESKAPEE pathogens poses significant clinical challenges, especially in polymicrobial infections. Bacteriophage-derived endolysins offer promise in combating this crisis, but face practical hurdles. Our study focuses on engineering endolysins from a Klebsiella pneumoniae phage, fusing them with ApoE23 and COG133 peptides. We assessed the resulting chimeric proteins’ bactericidal activity against ESKAPEE pathogens in vitro . ApoE23-Kp84B (CHU-1) reduced over 3 log units of CFU for A. baumannii , E. faecalis , K. pneumoniae within 1 h, while COG133-Kp84B (CHU-2) showed significant efficacy against S. aureus . COG133-L1-Kp84B, with a GS linker insertion in CHU-2, exhibited outstanding bactericidal activity against E. cloacae and P. aeruginosa . Scanning electron microscopy revealed alterations in bacterial morphology after treatment with engineered endolysins. Notably, CHU-1 demonstrated promising anti-biofilm and anti-persister cell activity against A. baumannii and E. faecalis but had limited efficacy in a bacteremia mouse model of their coinfection. Our findings advance the field of endolysin engineering, facilitating the customization of these proteins to target specific bacterial pathogens. This approach holds promise for the development of personalized therapies tailored to combat ESKAPEE infections effectively.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Tuberculosis, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
- Clinical Research Center, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Infectious Diseases, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Laboratory Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of Clinical Laboratory, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Zitieren
APA
Chen, W., Han, L. M., Chen, X. Z., Yi, P. C., Li, H., Ren, Y. Y., Gao, J. H., Zhang, C. Y., Huang, J., Wang, W. X., Hu, Z. L., & Hu, C. M. (2024). Engineered endolysin of Klebsiella pneumoniae phage is a potent and broad-spectrum bactericidal agent against “ESKAPEE” pathogens. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1397830
Vancouver
Chen W, Han LM, Chen XZ, Yi PC, Li H, Ren YY, et al. Engineered endolysin of Klebsiella pneumoniae phage is a potent and broad-spectrum bactericidal agent against “ESKAPEE” pathogens. Frontiers in Microbiology. 2024;15. doi:10.3389/fmicb.2024.1397830
BibTeX
@article{Chen2024,
author = {Chen, Wei and Han, Li-Mei and Chen, Xiu-Zhen and Yi, Peng-Cheng and Li, Hui and Ren, Yun-Yao and Gao, Jing-Han and Zhang, Cai-Yun and Huang, Jing and Wang, Wei-Xiao and Hu, Zhi-Liang and Hu, Chun-Mei},
title = {Engineered endolysin of Klebsiella pneumoniae phage is a potent and broad-spectrum bactericidal agent against “ESKAPEE” pathogens},
journal = {Frontiers in Microbiology},
year = {2024},
volume = {15},
doi = {10.3389/fmicb.2024.1397830}
}
EUVIMED